Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response

Journal of Rheumatology

Volumn 37, Issue 5, 2010, Pages 911-916

  Scarsi, Mirko ^a   Ziglioli, Tamara ^a   Airo, Paolo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Abatacept; CD28 negative T cells; Disease activity score; Rheumatoid arthritis; T lymphocytes

Indexed keywords

ABATACEPT; ASCORBIC ACID; C REACTIVE PROTEIN; CD28 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; METHOTREXATE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG WITHDRAWAL; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; FRAGILITY FRACTURE; HUMAN; IMMUNOPHENOTYPING; LYMPHOCYTE DIFFERENTIATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; ANTIGENS, CD28; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CELL COUNT; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 77951785328     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091176     Document Type: Article

References (34)

1. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212. (Pubitemid 23115006)
2. Crispin J, Tsokos GC. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun Rev 2009;8:190-195
3. Azuma M, Phillips JH, Lanier LL. CD28- T lymphocytes. J Immunol 1993;150:1147-1159
4. Hoshino T, Yamada A, Honda J, Imai Y, Nakao M, Inoue M, et al. Tissue-specific distribution and age-dependent increase of human CD11b+ T cells. J Immunol 1993;151:2237-2246 (Pubitemid 23235697)
5. Saukkonen JJ, Kornfeld H, Berman JS. Expansion of a CD8+CD28- cell population in the blood and lung of HIV-positive patients. J Acquir Immune Defic Syndr 1993;6:1194-1204
6. Choremi-Papadoupoulou H, Viglis V, Gargalianos P, Kordossis Y, Iniotaki-Theodoraki A, Kosmidis J. Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV infection. J Acquir Immune Defic Syndr 1994;7:245-253 (Pubitemid 2048250)
7. Brugnoni D, Prati E, Malacarne F, Gorla R, Airò P, Cattaneo R. The primary response to HIV infection is characterized by an expansion of activated CD8+ CD28- cells. AIDS 1996;10:104-106 (Pubitemid 26016412)
8. Brugnoni D, Airò P, Timpano S, Malacarne F, Ugazio AG, Cattaneo R, et al. CD8+CD28- T cells in vertically HIV-infected children. Clin Exp Immunol 1997;109:412-415
9. Kern F, Ode-Hakim S, Vogt K, Hoeflich C, Reinke P, Volk HD. The enigma of CD57+CD28- T cell expansion - anergy or activation? Clin Exp Immunol 1996;104:180-184
10. Borthwick NJ, Bofill M, Hassan I, Panayiotidis P, Janossy G, Salmon M, et al. Factors that influence activated CD8+ T cell apoptosis in patients with acute herpesvirus infections: loss of costimulatory molecules CD28, CD5 and CD6 but relative maintenance of Bax and Bcl-x expression. Immunology 1996;88:508-515
11. Kaneko H, Saito K, Hashimoto H, Yagita H, Okumura K, Azuma M. Preferential elimination of CD28+ T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis. Clin Exp Immunol 1996;106:18-29. (Pubitemid 26359886)
12. Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996;97:2027-2037
13. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 1997;40:1106-1114 (Pubitemid 27242298)
14. Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, et al. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004;109:2744-2748 (Pubitemid 38737922)
15. Linsley PS, Bradshaw J, Urnes M, Grosmaire L, Ledbetter J. CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling. J Immunol 1993;150:3161-3169 (Pubitemid 23129694)
16. Lake RA, O'Hehir RE, Verhoef A, Lamb JR. CD28 mRNA rapidly decays when activated T cells are functionally anergized with specific peptide. Int Immunol 1993;5:461-466 (Pubitemid 23162515)
17. Lloyd TE, Yang L, Tang DN, Bennett T, Schober W, Lewis DE. Regulation of CD28 costimulation in human CD81 T cells. J Immunol 1997;158:1551-1558 (Pubitemid 127469507)
18. Fiorentini S, Malacarne F, Ricotta D, Licenziati S, Solis AA, Ausenda S, et al. Generation of CD28- cells from long-term-stimulated CD8+CD28+ T cells: a possible mechanism accounting for the increased number of CD8+CD28+ T cells in HIV-1-infected patients. J Leukoc Biol 1999;65:641-648
19. Vingerhoets JH, Vanham GL, Kestens LL, Penne GG, Colebunders RL, Vandenbruaene MJ, et al. Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 downregulation on CD8+ T cells. Clin Exp Immunol 1995;100:425-433
20. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-712 (Pubitemid 129515761)
21. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4+ T Cells. J Exp Med 2001;194:1711-1719 (Pubitemid 34028651)
22. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003;101:4260-4266 (Pubitemid 36857786)
23. Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of memory T cells from childhood to old age: Central and effector memory cells in CD4+ versus effector memory and terminally differentiated memory cells in CD8+ compartment. Mech Ageing Dev 2006;27:274-281 (Pubitemid 43214500)
24. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-1915
25. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123 (Pubitemid 41317434)
26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
27. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-960
28. Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM, Goronzy JJ. Modulation of CD28 expression with anti-tumor necrosis factor a therapy in rheumatoid arthritis. Arthritis Rheum 2005;52:2996-3003. (Pubitemid 41447078)
29. Gerli R, Bartoloni-Bocci E, Shoenfeld Y. Effect of tumor necrosis factor a inhibition on CD28 surface expression on CD4+ T cells. Arthritis Rheum 2006;54:3060-3061 (Pubitemid 44497790)
30. Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68;1220-1227
31. Zhang X, Nakajima T, Goronzy JJ, Weyand CM. Tissue trafficking patterns of effector memory CD4+ T cells in rheumatoid arthritis. Arthritis Rheum 2005;52:3839-3849 (Pubitemid 41798222)
32. Gerli R, Vaudo G, Bartoloni-Bocci E, Schillaci G, Bistoni O, Shoenfeld Y. Different roles for anti-cyclic citrullinated peptide antibodies and CD4+CD28null cells in the acceleration of atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009;60:631-632
33. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000;101:2883-2888 (Pubitemid 30415876)
34. Westhovens R, Kremer JM, Moreland L, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009;36:736-742